title: Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
abstract: Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check-points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell-targeted therapies.
authors: Centre for Immunology and Infectious Disease, Barts and The London School of Medicine and Dentistry, Blizard Institute, London, UK. a.vossenkaemper@qmul.ac.uk
authors: A
authors: A
authors: Vossenkämper
authors: P M K
authors: PM
authors: Lutalo
authors: J
authors: J
authors: Spencer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000276:immunology* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D004311:Double-Blind Method; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D018655:Lymphocyte Count; D008212:Lymphocyte Depletion / Q000379:methods; D008221:Lymphoid Tissue / Q000276:immunology / Q000473:pathology; D038041:Lymphopoiesis; D051379:Mice; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; C448700:epratuzumab; D000069283:Rituximab; C511911:belimumab